Literature DB >> 6725965

Clostridium difficile-associated diarrhoea.

R P Brettle, E Wallace.   

Abstract

During the course of 1 year, Clostridium difficile was isolated from 145 (4 per cent) of 3591 faecal specimens submitted to a hospital routine bacteriology laboratory. These C. difficile positive specimens came from 95 patients or 10.99 per cent of 864 patients investigated for suspected gastroenteritis. In a control population of 318 persons C. difficile was isolated from only 10 of them or 3.1 per cent; this difference was statistically significant. We conclude that as this increase in the isolation of C. difficile from patients with diarrhoea is significant and is about as frequent as that of Campylobacter spp., faecal specimens submitted for routine bacteriology should also be cultured for C. difficile . As with diarrhoea caused by other enteric pathogens, most C. difficile -associated episodes of diarrhoea are mild and spontaneously reversible but approximately 20 per cent of patients have prolonged diarrhoea and may benefit from treatment.

Entities:  

Mesh:

Year:  1984        PMID: 6725965     DOI: 10.1016/s0163-4453(84)92443-5

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  4 in total

1.  Effect of antibiotic concentration in a selective medium on the isolation of Clostridium difficile from faecal specimens.

Authors:  P N Levett
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

Review 2.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

Review 3.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

4.  Mammalian epithelial cell line kit for detection of Clostridium difficile toxin.

Authors:  P Walpita; G F Billman; H F Krous
Journal:  J Clin Microbiol       Date:  1993-02       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.